In July ----, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare business. ...Also in July, according to the timetable set by the law of modernisation of France s health system, Hospital Grouping by Territories (GHT), a new mode of cooperation and integration of public health services across a territory, were formally established throughout France. In the same month, France s Minister of Health Marisol Touraine launched a national strategy under the concept of e-health ---- that will seek to enable making appointments and payments online, simplifying procedures for patients, enhancing tele-monitoring and telemedicine and the use of Big Data in diagnosis, among other objectives. Valneva announced that it has successfully generated a highly purified inactivated vaccine candidate against the Zika virus in July ----, an early advantage in development that will give Valneva options for acquisition or partnership with a larger company. ...In the same month, France s Minister of Health Marisol Touraine launched a national strategy under the concept of e-health ---- that will seek to enable making appointments and payments online, simplifying procedures for patients, enhancing tele-monitoring and telemedicine and the use of Big Data in diagnosis, among other objectives. Valneva announced that it has successfully generated a highly purified inactivated vaccine candidate against the Zika virus in July ----, an early advantage in development that will give Valneva options for acquisition or partnership with a larger company.
...BMI View: The UK vote to leave the EU will weigh on France s economic growth over the next few quarters, which in turn will pose downside risks to our pharmaceutical and healthcare sector forecasts. Despite the large pharmaceutical market and high drug spending per capita, which will continue to make France a major global market for drugmakers, market expansion will only resume at a slow pace over the next few years, with return to marginal positive growth in ----. ...BMI View: The UK vote to leave the EU will weigh on France s economic growth over the next few quarters, which in turn will pose downside risks to our pharmaceutical and healthcare sector forecasts. Despite the large pharmaceutical market and high drug spending per capita, which will continue to make France a major global market for drugmakers, market expansion will only resume at a slow pace over the next few years, with return to marginal positive growth in ----. In line with our view in recent quarters, the rate of investment growth in France s pharmaceutical sector has remained relatively subdued in H---, while this trend will likely continue over the coming quarters, in part due to sluggish labour market reform. ...Despite the large pharmaceutical market and high drug spending per capita, which will continue to make France a major global market for drugmakers, market expansion will only resume at a slow pace over the next few years, with return to marginal positive growth in ----. In line with our view in recent quarters, the rate of investment growth in France s pharmaceutical sector has remained relatively subdued in H---, while this trend will likely continue over the coming quarters, in part due to sluggish labour market reform.
...In July ----, officials from the cities of Strasbourg and Lyon added their French locations to the list of candidate cities for the new headquarters of the European Medicines Agency following Britain s vote to leave the EU. � Also in July, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December ---- which consists of an exchange of Sanofi s animal health business and Boehringer Ingelheim s consumer healthcare (CHC) business, completing in this way a major milestone before the closing of the transaction expected by year-end ----. ...
All information contained in this publication is copyrighted in the name of Business Monitor International Ltd, and as such no part of this publication may be reproduced, repackaged, redistributed, resold in whole or in any part, or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping, or by information storage or retrieval, or by any other means, without the express written consent of the publisher. ...